The initial phase focused on establishing a strong foundation through the undergraduate B.Pharm programme, followed by the introduction of the D.Pharm programme in the fourth year. Subsequently, sustained efforts were undertaken to bridge gaps between regulatory requirements and best institutional practices. To strengthen academic and research capabilities, advanced analytical instruments — including High Performance Liquid Chromatography (HPLC) — were installed, thereby upgrading laboratory facilities to a full-fledged standard.

As part of its infrastructural and regulatory development, the institution plans to obtain all mandatory statutory certifications — namely the Pollution Control Board Certificate, Fire and Safety Certificate, Persons with Disabilities (PwD) Certificate, Alcohol Licence, and Poison Permit — during 2025. The rear boundary wall was completed in 2025, and significant upgrades were carried out in the museum and computer centre. In parallel, the institution is working towards achieving a minimum of 50% pass percentage across all semesters, a prerequisite for applying for postgraduate programmes such as M.Pharm (Pharmacy Practice) and Pharm.D in 2026.

The institution's primary strategic objective is to secure university approval for postgraduate programmes, including M.Pharm (Pharmacy Practice) and Pharm.D, within the next two years. To support this goal and enhance academic quality and governance, the College aims to obtain ISO 21001 certification within the same timeframe. These initiatives will also facilitate participation in the National Institutional Ranking Framework (NIRF).

Simultaneously, the institution plans to establish Memoranda of Understanding (MoUs) with pharmaceutical industries, professional bodies, non-governmental organizations, and voluntary organizations engaged in social development — expanding further from the five MoUs currently signed. These collaborations are intended to strengthen research capacity, mentor scholars in developing competitive research proposals, and secure external funding from national and international research agencies.

Looking ahead, the institution proposes to introduce a language laboratory to enhance students' English communication skills. The computer laboratories will be further upgraded with advanced software to equip students with competencies relevant to emerging interdisciplinary domains such as business analytics, bioinformatics, and biostatistics. The academic vision also includes training in dissolution studies, pharmacokinetic challenges, and emerging areas of clinical research such as network pharmacology and drug repurposing.

In addition, efforts are underway to constitute an Institutional Ethics Committee (IEC) and obtain approval from the Central Drugs Standard Control Organization (CDSCO), thereby enabling pharmacy practice–oriented doctoral research and health policy research. Concurrently, the hospital pharmacy is proposed to be upgraded into a PCI-approved training centre for pharmacists.

The institution aims to achieve ISO 21001 certification and NAAC accreditation by 2027, paving the way for its transformation into a centre of excellence in pharmacy education, research, and professional practice.